IP Library › Granted Patent US 12,180,224
Granted Patent B2
US 12,180,224 · App. 18/121,886 · Granted Dec 31, 2024

Thienopyrimidine derivatives and production methods thereof

Inventors: Koichiro Fukuoka (Osaka, JP); Kazuhiro Miwa (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited
C07D495/04C07D333/38C07D409/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,180,224
App. No.
18/121,886
Granted
Dec 31, 2024
Kind
B2
Abstract

The present invention provides a production method of a thienopyrimidine derivative or a salt thereof which has a gonadotropin releasing hormone (GnRH) antagonistic action with high quality in high yield. The present invention provides a method of producing a thienopyrimidine derivative, which comprises reacting 6-(4-aminophenyl)-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione or salt thereof, 1,1′-carbonyldiimidazole or a salt thereof and methoxyamine or a salt thereof, and the like.

Claims (23)

1. A compound represented by the formula (I)

or a salt thereof, wherein R 1 is a C1-6 alkoxy group.

2. The compound of claim 1 or salt thereof, wherein R 1 is a methoxy group.

3. The compound of claim 1 or salt thereof, wherein R 1 is an ethoxy group.

4. The compound of claim 1 or salt thereof, wherein R 1 is a C3 alkoxy group.

5. The compound of claim 1 or salt thereof, wherein R 1 is a C4 alkoxy group.

6. The compound of claim 1 or salt thereof, wherein R 1 is a C5 alkoxy group.

7. The compound of claim 1 or salt thereof, wherein R 1 is a C6 alkoxy group.

8. A method of producing the compound of claim 3 , or a salt thereof, which comprises reacting ethyl 2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate, or a salt thereof, with N-bromosuccinimide and a radical initiator, and reacting the obtained ethyl 4-bromomethyl-2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-5-(4-nitrophenyl)thiophene-3-carboxylate, or salt thereof, with dimethylamine or a salt thereof.

9. The method of claim 8 , wherein the N-bromosuccinimide is used in an amount in the range of 1.0 to 1.5 molar equivalents per molar equivalent of the ethyl 2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof.

10. The method of claim 8 , wherein the reaction of ethyl 2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof with N-bromosuccinimide and the radical initiator is performed in the presence of trifluoromethylbenzene.

11. The method of claim 10 , wherein the trifluoromethylbenzene is used in an amount in the range of 0.1 mL to 1.0 mL per 1 mmol of the ethyl 2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof.

12. The method of claim 8 , wherein the radical initiator is 2,2′-azobis (2,4-dimethylvaleronitrile).

13. The method of claim 12 , wherein the 2,2′-azobis(2,4-dimethylvaleronitrile) is used in an amount in the range of 0.01 to 0.2 molar equivalents per molar equivalent of the ethyl 2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof.

14. The method of claim 8 , wherein the radical initiator is 2,2′-azobisisobutyronitrile.

15. The method of claim 8 , wherein the reaction of ethyl 2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-4-methyl-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof with N-bromosuccinimide and the radical initiator is performed in a solvent.

16. The method of claim 15 , wherein the solvent comprises ethyl acetate, carbon tetrachloride, dichloromethane, dichloroethane, chlorobenzene, or acetonitrile.

17. The method of claim 8 , wherein the dimethylamine is used in an amount in the range of 1.0 to 3.0 molar equivalents per molar equivalent of the ethyl 4-bromomethyl-2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof.

18. The method of claim 8 , wherein the dimethylamine is used in an amount in the range of 1.2 to 1.8 molar equivalents per molar equivalent of the ethyl 4-bromomethyl-2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof.

19. The method of claim 8 , wherein the reaction of the ethyl 4-bromomethyl-2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof with dimethylamine or salt thereof is performed in the presence of a solvent.

20. The method of claim 19 , wherein the solvent comprises dimethylformamide, dimethylacetamide, or tetrahydrofuran.

21. The method of claim 8 , wherein the reaction of the ethyl 4-bromomethyl-2-[(2,6-difluorobenzyl) ethoxycarbonylamino]-5-(4-nitrophenyl)thiophene-3-carboxylate or salt thereof with dimethylamine or salt thereof is performed in the presence of a base.

22. The method of claim 21 , wherein the base is triethylamine or diisopropylethylamine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2023
From: FUKUOKA, KOICHIRO; MIWA, KAZUHIRO; SASAKI, TSUYOSHI; KOMURA, FUMIYA
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 063126/0760 →
Priority Claims (1)
JP 2012-217679 · Sep 28, 2012 · national
Continuity (7)
Continuation 17694635 · Mar 14, 2022
Continuation 17349584 · Jun 16, 2021
Continuation 16710390 · Dec 11, 2019
Continuation 16116804 · Aug 29, 2018
Division 15481505 · Apr 7, 2017
Division 14432188
Related Publication 20230212184A1 · Jul 6, 2023
Cited By (6)
US 12,325,714 US 12,336,990 US 12,551,447 US 12,629,370 US 12,655,154 US 12,735,430